Ascendiant initiated coverage of Allarity (ALLR) with a Buy rating and $9 price target The firm sees large market opportunities for the company’s DRP platform and Stenoparib drug. It believes positive clinical trial data in 2025 and 2026 will be catalysts for the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLR: